Match Document Document Title
9040668 Anti-serum albumin binding variants  
The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions,...
9040054 Hypoallergenic molecules  
The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues...
9034339 Nucleic acid and amino acid sequences, and vaccine for the control of ectoparasite infestations in fish  
The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a...
9034822 Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds  
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
9034338 Nucleic acid and amino acid sequences, and vaccine for the control of ectoparasite infestations in fish  
The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a...
9034341 Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions  
The invention relates to methods for controlling the glycosylation of a RAGE fusion protein. The invention also relates to compositions comprising an amount of a RAGE fusion protein where at least...
9028835 Copolymers for suppression of autoimmune diseases, and methods of use  
Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. The random copolymers have amino acids alanine, lysine and one or more of the...
9023363 A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines  
The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1...
9017660 Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors  
This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
9017693 Apoptotically active peptides  
Specific amino acid sequences and peptides and/or peptide mimetics deducted therefrom influencing apoptosis, and the use thereof for the production of pharmaceuticals as diagnostic tools are shown.
9011869 Hybrid and tandem expression of Neisserial proteins  
Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino...
9006185 Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases  
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences,...
8999347 Vaccines for malaria  
The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections,...
9000139 Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer  
A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide...
8999348 Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues  
The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with...
8999346 Immunogenic control of tumours and tumour cells  
The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the...
8993266 Proproteins activatable interferon alpha  
The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which...
8992937 Disulfide trap MHC class I molecules and uses therefor  
A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some...
8993519 Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor  
Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and...
8992938 Genes and proteins of Brachyspira hyodysenteriae and uses thereof  
Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or...
8993727 Carrier immunoglobulins and uses thereof  
Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells,...
8993524 Compositions and methods for targeted immunomodulatory antibodies and fusion proteins  
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are...
8986702 Antibodies and processes for preparing the same  
Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments,...
8980274 Ehrlichia canis DIVA (differentiate infected from vaccinated animals)  
The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also...
8980286 Multiple variants of meningococcal protein NBM1870  
Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it...
8980275 Targeted heterologous antigen presentation on calicivirus virus-like particles  
The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention...
8974797 Virus-like particles as vaccines for paramyxovirus  
The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are...
8974794 C(epsilon)mX peptides for inducing immune responses to human mIgE on B lymphocytes  
The invention pertains to methods of using CεmX peptides (e.g., GLAGGSAQSQRAPDRVL; SEQ ID NO:2) that can bind effectively induce immune responses to membrane-bound IgE (mIgE) expressed on the...
8961991 Anti-CD40 targeted fusion proteins  
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to...
8961981 Targeting the neuromuscular junction for treatment  
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular...
8962811 Growth hormone and interferon-alpha 2 glycoproteins produced in plants  
Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive...
8961992 Epsigam fusion protein  
Epsi-gam provides a novel fusion protein with the ability to cross-link either of the FcεRI or FcεRII cell surface receptors with an FcγRIIb cell surface receptor in order to block IgE-mediated...
8961987 Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies  
Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens...
8961988 Compositions and methods for the treatment or prevention of hepatitis B virus infection  
Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well...
8956622 Peptidic antagonists of class III semaphorins/neuropilins complexes  
The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein...
8956621 Compositions and methods for treatment of cervical dysplasia  
The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a...
8956611 Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease  
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS...
8956623 Recombinant fusion interferon for animals  
The present invention relates to a recombinant fusion interferon for animals, a pharmaceutical composition thereof, and the use of the recombinant fusion interferon. The recombinant fusion...
8956618 Vaccine vectors and methods of enhancing immune responses  
Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also...
8951534 Vaccines for the treatment of neoplasias from viral capsids of birnavirus containing antigens of the human papillomavirus  
The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric...
8951532 A25 bacteriophage lysin  
The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life...
8951972 FGFR1 extracellular domain combination therapies for lung cancer  
Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one...
8951530 Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies  
The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from D. pteronyssinus useful for the prevention and treatment of allergies,...
8945584 Cell culture system of a hepatitis C genotype 3a and 2a chimera  
A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7...
8945589 Immunogenic compositions for Streptococcus agalactiae  
This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a...
8945577 Fusion proteins and combination vaccines comprising Haemophilus influenzae Protein E and Pilin A  
The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic...
8945575 Treatment of IgE-mediated disease  
The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides...
8945580 Yersinia pestis antigens, vaccine compositions, and related methods  
The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis. The present invention provides pharmaceutical compositions of such antigens and/or...
8945579 Methods of treatment with compositions that include hemagglutinin  
Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a...
8936792 Pseudomonas exotoxin a with reduced immunogenicity  
The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.